文献速递湿疹皮炎与荨麻疹

TLL-018治疗抗组胺药应答不佳的慢性自发性荨麻疹的Ib期随机对照试验

Safety and efficacy of the selective tyrosine kinase 2/Janus kinase 1 inhibitor TLL-018 in patients with moderate-to-severe chronic spontaneous urticaria with inadequate response to H1 antihistamines: a phase Ib, randomized, double-blind, placebo-controlled pilot study.
PubMed 文献 · Br J Dermatol · 2026-01-01

这项多中心、双盲、随机、安慰剂对照的Ib期试验纳入41例抗组胺药应答不佳的中重度慢性自发性荨麻疹患者,按1:1:1接受TLL-018 10 mg、30 mg或安慰剂口服每日两次。主要终点为安全性;第4周时TLL-018组瘙痒和风团较安慰剂组改善,第12周多数患者达到UAS7≤6或UAS7=0。常见不良事件包括肌酸激酶升高、血脂升高、高血糖和尿潜血。

要点

  • TLL-018 10 mg和30 mg每日两次在抗组胺药应答不佳的CSU患者中耐受性良好。
  • 第4周时TLL-018组UAS7、瘙痒和风团评分较基线的改善优于安慰剂。
  • 第12周时各TLL-018剂量组多数患者达到UAS7≤6或UAS7=0。

核心结论

  • TLL-018在抗组胺药应答不佳的中重度慢性自发性荨麻疹患者中耐受性良好且有效。

研究设计与样本

  • 多中心、双盲、随机、安慰剂对照、平行组Ib期试验(NCT05373355)。
  • 41例抗组胺药应答不佳的CSU患者按1:1:1随机接受TLL-018 10 mg、30 mg或安慰剂口服每日两次。
  • 4周后安慰剂组转换为TLL-018 20 mg并继续治疗8周。
  • 主要终点为安全性,次要终点包括第4周和第12周的UAS7≤6、UAS7=0及DLQI为0或1。

主要发现

  • 第4周时,10 mg组UAS7、每周瘙痒严重程度评分和每周风团严重程度评分较基线的安慰剂校正变化分别为-11.5、-8.0和-3.8。
  • 第4周时,30 mg组UAS7、每周瘙痒严重程度评分和每周风团严重程度评分较基线的安慰剂校正变化分别为-16.0、-9.0和-7.0。
  • 第12周时,安慰剂后20 mg组达到UAS7≤6和UAS7=0的比例分别为54%和39%。
  • 第12周时,10 mg组达到UAS7≤6和UAS7=0的比例分别为71%和64%。
  • 第12周时,30 mg组达到UAS7≤6和UAS7=0的比例分别为62%和54%。

关键数值与推荐

  • 常见治疗中出现的不良事件包括血清肌酸激酶升高、血脂升高、高血糖和尿潜血。

临床怎么用

  • 对于抗组胺药应答不佳的中重度CSU患者,TLL-018可能作为候选治疗选择。
  • 治疗期间需监测肌酸激酶、血脂、血糖和尿潜血等不良事件。

局限性

  • 本研究为Ib期试点试验,样本量较小(41例),需更大规模研究确认疗效和罕见不良反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic spontaneous urticaria (CSU) places a considerable burden on both patients and caregivers. Current treatments for CSU are inadequate for some patients. TLL-018, an oral tyrosine kinase 2/Janus kinase 1 (TYK2/JAK1) inhibitor, is currently being investigated as a potential treatment for CSU. OBJECTIVES: To evaluate the efficacy and safety of TLL-018 for treating moderate-to-severe CSU in patients with an inadequate response to antihistamines. METHODS: In this multicentre, double-blind, randomized, placebo-controlled, parallel-group pilot study (NCT05373355), patients with CSU who showed an inadequate response to antihistamines were given (1: 1: 1) 10 or 30 mg of TLL-018, or placebo, orally twice daily. After 4 weeks, patients on placebo were switched to TLL-018 20 mg and continued treatment for a further 8 weeks. The primary endpoint was safety, while secondary endpoints included efficacy measures, such as weekly Urticaria Activity Score (UAS7) ≤ 6, UAS7 = 0, and a Dermatology Life Quality Index score of 0 or 1, at weeks 4 and 12. RESULTS: Overall, 41 patients were randomly assigned to TLL-018 10 mg (n = 14), 30 mg (n = 13) or placebo (n = 14). At week 4, the placebo-adjusted change from baseline (analysed using Ancova) in UAS7, weekly Itch Severity Score and weekly Hive Severity Score was -11.5, -8.0 and -3.8, respectively, in the 10-mg TLL-018 group, and -16.0, -9.0 and -7.0, respectively, in the 30-mg group. At week 12, the proportions of patients achieving UAS7 ≤ 6 and UAS7 = 0 were 54% and 39%, respectively, in the placebo-then-20-mg group, 71% and 64% in the 10-mg group, and 62% and 54% in the 30-mg group. Common treatment-emergent adverse events included elevated serum creatine kinase and blood lipid levels, hyperglycaemia and urinary occult blood. CONCLUSIONS: TLL-018 was well tolerated and effective in treating moderate-to-severe CSU in patients who had an inadequate response to antihistamines. Chronic spontaneous urticaria is a common skin disease. It causes itchy weals or ‘hives’ on the body. During a flare, weals can appear on most days for more than 6 weeks. Up to 1 in 100 people worldwide live with chronic spontaneous urticaria. The current treatment, antihistamine pills, only works for some people. In this study, we investigated a new medicine called TLL-018. It blocks two proteins (TYK2 and JAK1) involved in inflammation. We wanted to see if it could treat adults whose hives did not improve using antihistamines. The study involved 41 adults with chronic spontaneous urticaria. They were randomly assigned to take either 10 mg or 30 mg of TLL-018, or a placebo (inactive) pill, twice a day for 4 weeks. After that, people taking the placebo were given 20 mg of TLL-018 instead, for 8 more weeks. After 4 weeks of treatment, people in the TLL-018 groups reported less itching and fewer hives than people in the placebo group. By week 12, more than half of the participants taking any dose of TLL-018 had very mild or no symptoms. The most common side-effects were small rises in blood sugar, cholesterol and muscle enzyme levels. Importantly, these side-effects were usually mild and reversible. In conclusion, our study findings suggest that TLL-018 was well tolerated. It reduced hives, itch and life disruption for people with chronic spontaneous urticaria. Larger studies are now needed to confirm these benefits and to look for any rare side-effects.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Yao X, Liu Y, Luo Y, et al. Safety and efficacy of the selective tyrosine kinase 2/Janus kinase 1 inhibitor TLL-018 in patients with moderate-to-severe chronic spontaneous urticaria with inadequate response to H1 antihistamines: a phase Ib, randomized, double-blind, placebo-controlled pilot study. Br J Dermatol. 2026. PMID: 41834239. doi:10.1093/bjd/ljag092

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。